<DOC>
	<DOCNO>NCT00231049</DOCNO>
	<brief_summary>This randomize , multi-center , sequential , dose-escalating study three dose cohort AG-707 . Individuals meet inclusion exclusion criterion eligibility randomize receive either AG-707 ( 80 µg dose ) , AG-707 QS-21 ( 80 µg dose ) , placebo , QS-21 . Each patient monitor safety specify protocol .</brief_summary>
	<brief_title>Trial Evaluating Safety , Tolerability Immune Response AG-707</brief_title>
	<detailed_description>Primary Objective : Determine overall safety profile three different dose level AG-707 vaccination ( without adjuvant , QS-21 ) 80 , 240 400 µg compare placebo QS-21 alone HSV-2 seropositive adult . Secondary Objective : Determine immune response AG-707 vaccination ( without QS-21 ) dose cohort 80 , 240 , 400 µg compare placebo QS-21 alone .</detailed_description>
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>Patients must seropositive HSV2 ( +/ HSV1 ) document history clinically active genital herpes ( least one prior outbreak ) . Patients must seronegative HIV . Patients must seronegative hepatitis B C Have baseline chemistry hematology ( hemoglobin , white blood cell ( WBC ) , absolute neutrophil count ( ANC ) , eosinophils ) within normal limit ; prothrombin time ( PT ) partial thromboplastin time ( PTT ) upper limit normal ( ULN ) , platelet low limit normal ( LLN ) . Basophils , lymphocytes monocyte must within 1.2 x ULN 0.8 x LLN consider clinically significant investigator . Total creatine phosphokinase ( CPK ) laboratory value &lt; 1.25X upper limit normal ( accord normal reference range Central Laboratory ) baseline ( Screening PreStudy Visit ) consider clinically significant Investigator . Patients must take antiviral therapy . Must age 18 50 year age willing either use effective method contraception abstain sexual activity 28week duration trial . Severe active infection , compromise cardiopulmonary function , serious medical illness , opinion Principal Investigator , would prevent study completion . History HSV infection eye ( herpes simplex interstitial keratitis uveitis ) , herpesassociated erythema multiforme . History immune suppression autoimmune disorder . Concomitant use systemic corticosteroid immunosuppressive medication ( include nasal inhaled steroid ) . The use nasal steroid seasonal rhinitis acceptable . Patients know hypersensitivity allergy acyclovir valacyclovir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Genital Herpes</keyword>
	<keyword>HSV-2 Seropositive</keyword>
	<keyword>Vaccine</keyword>
</DOC>